RecruitingPhase 2NCT02616302
A Study to Check the Safety of Dexlansoprazole and Learn if it Can Treat Symptomatic Nonerosive Gastroesophageal Reflux Disease in Children 2 to 11 Years Old
Studying NLRP3-associated autoinflammatory disease
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Takeda
- Principal Investigator
- Study DirectorTakeda
- Intervention
- Dexlansoprazole(drug)
- Enrollment
- 70 target
- Eligibility
- 2-11 years · All sexes
- Timeline
- 2023 – 2027
Study locations (30)
- Childrens Center for Digestive Health Care, LLC, Mobile, Alabama, United States
- University of Utah/ Primary Childrens Hospital, San Francisco, California, United States
- Gastrointestinal Associates, PA, Centennial, Colorado, United States
- Envision Clinical Research, LLC, Miami, Florida, United States
- GI For Kids, Atlanta, Georgia, United States
- Strada Patient Care Center, Department of Pediatric Gastroenterology, Chicago, Illinois, United States
- Childrens Hospital of The Kings Daughters, Jackson, Mississippi, United States
- Maspons Pediatric Gastro, Manchester, New Hampshire, United States
- The University of Chicago, Cleveland, Ohio, United States
- Dartmouth-Hitchcock Manchester, Oklahoma City, Oklahoma, United States
- University of California San Francisco, Oklahoma City, Oklahoma, United States
- c/o Chelsea Campbell, RN, Knoxville, Tennessee, United States
- Vanderbilt University Medical Center,, Nashville, Tennessee, United States
- Oklahoma Pediatric Digestive Institute, El Paso, Texas, United States
- University Hospitals Cleveland Medical Center, Laredo, Texas, United States
- +15 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT02616302 on ClinicalTrials.govOther trials for NLRP3-associated autoinflammatory disease
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE1, PHASE2NCT07540338A Study to Investigate Lithium Brain/Plasma Pharmacokinetics and Safety of an AL001 Oral Capsule Compared to a Marketed Immediate-release Lithium Carbonate Capsule in Subjects With Bipolar I DisorderAlzamend Neuro, Inc.
- RECRUITINGPHASE3NCT07343778A Clinical Trial Evaluating the Safety of Hydronidone Capsules in Patients With Hepatic Fibrosis and Liver CirrhosisBeijing Continent Pharmaceutical Co, Ltd.
- RECRUITINGPHASE2NCT07364448A Study to Evaluate the Safety of Hydronidone Capsules in Patients With Liver FibrosisBeijing Continent Pharmaceutical Co, Ltd.
- RECRUITINGNANCT06544018Circadian Rhythm Deregulation in Patients With CAPSHospices Civils de Lyon
- RECRUITINGNANCT07203963Additional Effects of Niel-asher Technique on Patients With Adhesive CapsulitisRiphah International University
- RECRUITINGPHASE1NCT07532135Safety of Mulberry Leaf Extract Capsule on Blood Glucose Control in Healthy VolunteerChulalongkorn University
- RECRUITINGPHASE4NCT07114120Clinical Study on the Treatment of Stable Bronchiectasis With Bailing Capsules Combined With Guben Kechuan GranulesSecond Affiliated Hospital, School of Medicine, Zhejiang University
- RECRUITINGPHASE3NCT06930794A Study of Vebreltinib and Platinum-Containing Double Agents in Subjects With MET-PositiveBeijing Pearl Biotechnology Limited Liability Company
See all trials for NLRP3-associated autoinflammatory disease →